Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

BMS-188797 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Treatment

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2000 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00005611
First received: May 2, 2000
Last updated: July 23, 2008
Last verified: August 2000

May 2, 2000
July 23, 2008
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00005611 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
BMS-188797 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Treatment
Phase I Study of BMS-188797 in Patients With Advanced Malignancies

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase I trial to study the effectiveness of BMS-188797 in treating patients who have advanced solid tumors that have not responded to previous treatment.

OBJECTIVES: I. Determine the maximum tolerated dose and recommended phase II dose, dose limiting toxicities, and safety of BMS-188787 in patients with nonhematologic malignancies. II. Determine the plasma pharmacokinetics of BMS-188797 in these patients. III. Describe any antitumor activity of this treatment in these patients.

OUTLINE: This is a dose escalation study. Patients receive BMS-188797 IV over 1 hour. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of BMS-188797 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicities. Patients are followed every 4 weeks until toxicities resolve, and then at the investigator's discretion.

PROJECTED ACCRUAL: Approximately 20-40 patients will be accrued for this study over 12-18 months.

Interventional
Phase 1
Primary Purpose: Treatment
Unspecified Adult Solid Tumor, Protocol Specific
Drug: BMS-188797
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
Not Provided
Not Provided
Not Provided

DISEASE CHARACTERISTICS: Histologically or cytologically confirmed nonhematologic malignancy unresponsive to existing therapy or for which no curative therapy exists Patients with prostate cancer must have withdrawn from antiandrogen therapy (flutamide, bicalutamide) for at least 4 weeks and must have progressive disease Measurable or evaluable disease No active brain metastases (e.g., cerebral edema, progression from prior imaging study, requirement for steroids, or clinical symptoms)

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At least 3 months Hematopoietic: Absolute neutrophil count at least 2,000/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL ALT and AST no greater than 2.5 times upper limit of normal (ULN) (unless due to hepatic metastases) Renal: Creatinine less than 1.5 times ULN Other: No serious uncontrolled medical disorder or active infection that would preclude study No hypersensitivity to agents containing polyoxyethylated castor oil (Cremophor EL) except in patients who received prior taxane therapy with premedication and did not experience greater than grade 1 hypersensitivity reaction Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior immunotherapy Chemotherapy: At least 4 weeks since prior chemotherapy (6 weeks since prior nitrosoureas, mitomycin, or carboplatin) Prior taxanes allowed No other concurrent chemotherapy Endocrine therapy: See Disease Characteristics At least 2 weeks since prior hormonal therapy No concurrent steroids No concurrent hormonal therapy (except leuprolide acetate for prostate cancer) Radiotherapy: At least 4 weeks since prior radiotherapy to 30% or more of bone marrow No concurrent radiotherapy Surgery: Not specified Other: No other concurrent investigational anticancer therapy

Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00005611
CDR0000067740, MCC-11836, BMS-CA159-001, MCC-IRB-5140, NCI-G00-1744
Not Provided
Not Provided
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
Study Chair: William S. Dalton, MD, PhD H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
August 2000

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP